Abstract: Alzheimer´s disease (AD) is one of the most discussed diseases of present time. Because of the aging of our population it is high threat for future. Due to this, new drugs combating AD are still developed. In this study, twelve bisquaternary isoquinolinium de-rivatives differing in the linker between two heteroarenium rings were synthesized and tested for their potency to inhibit brain cho-linesterases. According to the obtained in vitro results, the anticholinesterase activity grew up with the length of the connection chain. Possible binding to the enzyme cavity was described using software Autodock. Moreover, LogP and molecular volume of prepared com-pounds were predicted. As resulted, the highest probability of synthesized compounds to penetrate blood-brain barrier could be expected for the compound with linker having eight methylenes. Keywords: Quinolinium, Quaternary compounds, Inhibitor, Cholinesterase, Alzheimer´s disease, Anticholinergic. INTRODUCTION At present, there is increasing number of people suffering from diseases connecting with the increasing age. Among them, Alz-heimer´s disease (AD) is well discussed by the scientific commu-nity. It belongs along with cancer, AIDS and cardiovascular dis-eases among the highest threats influencing the whole population. Although this disease is known already for more than one hundred years, there is no treatment able to stop its degenerative progress. Currently, there are just few AD treatments (Donepezil, Galan-tamine, Rivastigmine, Tacrine, Memantine) approved by FDA. All of them, except Memantine, are potent inhibitors of acetylcho-linesterase (AChE; EC 3.1.1.7). Although the cholinergic approach is able to have only one- or two-year benefit, economically, one or two more years of the productive life are very important [1,2]. Due to this reason, development of new AChE inhibitors as new AD-drugs candidates is still possible approach how to combat AD [3-5]. During last years, there were published several articles discuss-ing penetration of quaternary compounds into the blood-brain bar-rier (BBB) [6-8]. Thanks to this, also quaternary compounds with increased lipophility could be considered as an alternative for treatment of AD or at least as its supplement. Recently, there were published several articles describing quaternary compounds (expe-cially pyridinium compounds) as potential AD treatment [9-12]. In 2004, we found that more potent inhibitors of AChE than pyridi-nium salts seem to be quaternary compounds with conjugated aro-matic rings (quinolinium, isoquinolinium or acridinium) [13]. Thanks to the added aromatic rings, also their lipophilicity is higher if compared with pyridinium compounds. And with the lipophilic-ity, hand in hand, higher penetration through the BBB can be ex-pected. Because of the fact that affinity of bisquaternary compounds is higher than that of monoquaternary ones, in this article, we turned our attention to bisquaternary isoquinolinium compounds differing in the length of the connection chain between two isoquinolines.